Partnerships

Lion Biotechnologies is actively seeking partnerships for the development and commercialization of its products. We believe our novel and versatile technology, promising clinical programs and strong intellectual property make us an attractive partnering candidate. We welcome inquiries from corporations, individuals, and academic institutions.

For more information, please contact us.

National Cancer Institute

National Cancer Institute

  • Cooperative Research and Development Agreement with Steven A. Rosenberg, MD, Chief, Surgery Branch
  • Exclusive rights to new adoptive cell therapy technologies for the treatment of metastatic melanoma
  • May conduct clinical trials at NCI
  • Access to all clinical data, manufacturing data and SOPs

National Institutes of Health

National Institutes of Health

  • Background Intellectual Property License
  • Worldwide, non-exclusive license for adoptive cell therapy technologies from National Institutes of Health

MedImmune

MedImmune

  • Phase 2a clinical program investigating combination of TIL and MedImmune’s PD-L1 inhibitor durvalumab
  • Preclinical research program evaluating the impact of MedImmune’s checkpoint antibodies on TIL expansion and anti-tumor activity

Karolinska

Karolinska

  • Exclusive worldwide rights to two international patent applications related to a specific combination of cytokines
  • Phase 1 clinical trials to treat glioblastoma and pancreatic cancer

Moffit Cancer Center

Moffit Cancer Center

  • Phase 2 clinical program investigating combination of TIL + ipi in metastatic breast cancer, clinical trial data expected soon
  • Phase 1 clinical program investigating combination of TIL + Opdivo in metastatic breast cancer ongoing

MD Anderson Cancer Center

MD Anderson Cancer Center

  • Multi-year alliance agreement 
  • Multi-arm clinical trials evaluating TIL therapy in ovarian cancer, various sarcomas and pancreatic cancer
  • Preclinical research collaboration focused on expansion of TIL from additional tumor types